Clinician-led engagement outperforms non-clinical call-center models, with “nurse ambassador” programs enabling escalation, ...
Dual BAFF/APRIL blockade targets upstream B-cell survival signaling to reduce production of galactose-deficient IgA1 and anti–Gd-IgA1 autoantibodies driving nephritogenic immune complexes. ORIGIN 3 ...
Bansi Nagji discusses the shifting science behind rare and orphan drug development, including what it takes for therapies to succeed well beyond launch. Bansi Nagji, CEO of PANTHERx Rare, explores how ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, explains how real-time data generated through direct-to-patient models are shaping pharma's commercial decisions. Direct-to-patient (DTP) ...
Medication nonadherence is common and costly, with higher rates in biologics for autoimmune disease (28–52%), reflecting intertwined barriers spanning beliefs, side effects, affordability, and ...
Only 18% of payers report using RWE in coverage decisions despite 80% expressing demand, reflecting a market access disconnect driven primarily by interpretability and usability barriers. Payers’ ...
This week's Pharma Pulse covers the launch of Medicare's GLP-1 Bridge, FDA's approval of the first regulatory T-cell therapy for chronic GVHD, seven companies tapped for FDA's PreCheck manufacturing ...
Deanna Horner, EVP of Enterprise DIRECT Strategy at EVERSANA, breaks down what's fueling pharma's embrace of direct-to-patient models. The direct-to-patient (DTP) channel has moved from experimental ...
Seven firms were selected for a two-phase FDA program linking new US manufacturing facilities to planned NDA/BLA/ANDA filings or supplements, targeting supply needs and unmet medical needs. Phase 1 ...
Capital is flowing into CGTs, while outpatient CAR-T delivery reached 45% in 2025, expanding the number of administration sites requiring specialized, time-critical logistics support. Maintaining vein ...
Gerren McHam of the API Innovation Center outlines what a whole-of-government approach to meaningful pharmaceutical supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results